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Abstract
As visual impairment (VI) due to adverse drug reactions (ADR) is rare in
adults and children, there is an incomplete evidence base to inform guidance
for screening and for counseling patients on the potential risks of medications.
We report on suspected drugs and the eye conditions found in a national study
of incidence of diagnosis of visual impairment due to suspected ADR. Case
ascertainment was via the British Ophthalmological Surveillance Unit (BOSU),
between March 2010 and February 2012, with follow-up after 6 months. Case
definition: any child or adult with bilateral or unilateral visual impairment due
to a suspected ADR, using distance acuity worse than Snellen 6/18 (logMAR
0.48) in the better eye (bilateral) or affected eye (unilateral). Anonymized
patient information on potential cases was provided by managing ophthalmolo-
gists, comprising visual status before and after suspected ADR, ophthalmic con-
dition attributable to the ADR, preexisting eye disease and prescribed
medications at the time of the ADR. Permanency and causality of the visual
impairment were confirmed by the managing clinician, after 6 months, using
the WHO Uppsala Monitoring Committee criteria. Over 2 years, 36 eligible
cases were reported of whom 23 had permanent VI. While most cases were due
to drugs known to have adverse side-effects, some were unanticipated sporadic
cases. Visual impairment due to ADRs is rare. However, with for example,
increasing polypharmacy in the elderly, monitoring of ocular ADRs, although
challenging, is necessary.
Abbreviations
ADR, adverse drug reactions; BL, blind; BOSU, British Ophthalmological Surveil-
lance Unit; DFO, desferrioxamine; EMB, ethambutol; ERG, electroretinogram; IOL,
intraocular lens; MHRA, Medicines and Healthcare products Regulatory Agency;
OLUL, off-label and unlicensed; SI, sight impaired; SSI, severely sight impaired;
SVI, severe visual impairment; TPA, tissue plasminogen activator; VEP, visual
evoked potential; VI, visual impairment; WHO, World Health Organisation; YCS,
yellow card scheme.
ª 2014 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
2014 | Vol. 3 | Iss. 1 | e00107
Page 1
Received: 22 August 2014; Revised: 2
October 2014; Accepted: 5 October 2014
Pharma Res Per, 3(1), 2014, e00107,
doi: 10.1002/prp2.107
doi: 10.1002/prp2.107
Introduction
Visual impairment as an adverse side-effect of medication
is rare but can lead to considerable individual and societal
burden. Acquiring robust data to identify and confirm a
relationship between a medication and an uncommon
adverse side-effect is challenging.
In the United Kingdom, medications are ‘monitored’
through the Medical and Health product Regulatory
Agency (MHRA). All serious suspected adverse drug reac-
tions (ADR) and any drug-related side-effect of a new
(black triangle) medication (Kelly 2009) are reported
using the voluntary Yellow Card Scheme (Medical and
Health product Regulatory Agency [MHRA); voluntary
Yellow Card Scheme [YCS]) to inform an anonymized
national database. However, as ocular ADRs are classified
by eye condition rather than functional impact or vision,
estimation of population incidence of visual impairment
due to these ADRs is not possible through this source.
We, therefore, carried out a national active surveillance
study of incidence of diagnosis of visual loss due to ADRs,
through British Ophthalmological Surveillance Unit
(BOSU), and have previously published a brief report on
the incidence and an evaluation of the national monitoring
of ADRs through the MHRA Yellow Card system, based on
voluntary reporting of events (Cumberland et al. 2014).
Our study found, as expected, that visual impairment
due to ADRs is rare in both adults and children and
while the majority of cases were due to drugs known to
have adverse side-effects a few were unanticipated spo-
radic cases. We report here on suspected drugs, eye con-
ditions and clinical detail relating to ADR cases at time of
notification and at follow-up, after 6 months. This
method of active surveillance has been able to provide
otherwise inaccessible information on visual loss due to
ADRs, including involvement of some medications previ-
ously not known to cause such ADRs.
Materials and Methods
Case definition
Any individual (child or adult) with newly diagnosed sig-
nificant visual loss which is suspected to be due to an ADR
to any prescribed medication (topical or systemic) (World
Health Organisation), to include any of the following:
bilateral or unilateral visual impairment due to suspected
ADR that is, patient eligible for certification as sight
impaired (SI) (partial sight) or severely sight impaired
(SSSI) (blind), based on acuity or visual fields, or patient
with distance acuity worse than Snellen 6/18 (logMAR
0.48) in the better eye if bilaterally affected or in the
affected eye if unilateral, (WHO modified taxonomy).
Patients with new ophthalmic signs and symptoms com-
patible with an ADR but without significant loss of vision
as defined above or patients with raised intra-ocular
pressure (IOP) or cataract due to topical or oral steroid
treatment (i.e., known and common dose-related side-
effect), were ineligible.
Case ascertainment
Active surveillance was carried out through BOSU over
24 months to February 2012, with 6-month follow-up data
collection completed by November 2012. BOSU was estab-
lished in 1997 and is administered by the Royal College of
Ophthalmologists in the UK. The mailing list of 850
Consultant Ophthalmologists and Associate Specialists
(hospital-based clinicians) and Senior Lecturers in Ophthal-
mology (academic clinicians) has been developed and is sys-
tematically updated. The aim is to involve every senior
doctor who may have clinical responsibility for patients
with rare ophthalmological conditions. A monthly BOSU
report card, listing all conditions under surveillance, is sent
to all those on the mailing list. Return of a card to BOSU,
reporting a case, triggers a notification to the study team
who send the reporting ophthalmologist a standardized
data collection form. There is no direct patient contact.
Procedures
At notification, information was requested on the patient’s
visual status prior and post the suspected ADR, the specific
ophthalmic condition attributable to the ADR, preexisting
eye disease, all medications being taken at the time of the
ADR, and the name of the suspected drug with details of
dose, duration. and administration route.
Six months after notification, reporting clinicians were
sent a follow-up data collection form. Information on
both the permanency of the visual impairment reported
and the probability of the causality of the ADR, using
the World Health Organisation-Uppsala Monitoring
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Committee assessment criteria (World Health Organisa-
tion 2013) was requested. This allowed sufficient time
after notification for completion of diagnostic tests and
any potential improvement in vision resulting from de-
challenge. Up to two reminders were sent to nonrespond-
ing ophthalmologists.
The research ethics committee of the UCL Institute of
Child Health and Great Ormond Street Hospital, London,
approved the study.
Results
Of 36 eligible cases notified through BOSU between March
2010 and February 2012, 18 were permanent cases (con-
firmed as permanent visual loss at 6 months) and 13 had
temporary visual impairment that is, vision recovered
above the eligibility criteria threshold after 6 months. Per-
manency was not confirmed in 5 cases as 6-month follow-
up data were not available. Thirteen of 35 (37%) cases
were male (1 case – missing data on sex). There were no
children and most cases were over 60 years of age (5
[15%] between 20 and 40 years, 11 [32%] aged 41–
60 years, and 18 [53%] at least 61 years). Three subjects
prescribed ethambutol (EMB) were of non-White ethnicity
(2 Indian and 1 African), and all others were White.
Ophthalmic conditions resulting from ADR
Of the 36 cases, 22 (61%), were reported as having optic
nerve disease (optic neuropathy/neuritis/atrophy), 4 had
maculopathy, 3 retinopathy, and 4 cases had angle-closure
glaucoma. Other conditions included severe anterior uve-
itis, ocular hypotony, and choroidal body detachments.
(Figure 1).
Permanent and temporary cases,
by suspected drug
Most reports involved drugs known to have adverse ocu-
lar side-effects but there were several other unanticipated
medications reported (Panel Table 1).
Ethambutol
Overall, 12 patients (median age 68.5, interquartile range
[55, 74.5]; 50% males) were reported with EMB-induced
optic neuropathy. In all cases, EMB was withdrawn after
the ADR event (1 with concurrent withdrawal of Isonia-
zid). Dosage ranged between 800 mg and 1.2 grammes
daily, median 1 gramme (4 cases; dosage not known). For
the 7 permanent cases, the median duration of adminis-
tration was 11 months (range 20 days to 18 months).
Using WHO-UMC criteria, 3/12 cases were certain, 6
‘probable/likely’, and 2 ‘possible’ ADRs due to EMB
(missing data for 1 temporary case).
Hydroxychloroquine and chloroquine
phosphate
Two patients, prescribed hydroxychloroquine, for sys-
temic lupus erythematosus and arthritis, had been taking
it for 1 and 2 months at 200 mg once and twice a day,
respectively. One patient, prescribed a 250 mg daily dose
of chloroquine phosphate for several years for arthritis,
was reported to have maculopathy with reduced visual
fields. One unconfirmed case had retinopathy after taking
hydroxychloroquine for more than 8 years concurrently
with other medications and it was reported that coexis-
ting renal impairment could have contributed. All cases
had severely affected electroretinograms (ERGs) and
abnormal (delayed) visual evoked potential (VEPs) indic-
ative of late toxicity.
Quinine
Two patients prescribed Quinine for night cramps were
reported to have had an adverse reaction due to a single
large dose, one deliberately self-administered and the
other taken in error in combination with alcohol.
Although administration errors, these cases are included
as they nevertheless caused VI.
One unconfirmed case with coexisting renal impair-
ment had retinopathy and bilateral retinal pigment epi-
thelium atrophy after taking 300 mg quinine sulfate daily,
for night cramps, for over 5 years concurrently with other
medications. The other patient, with optic neuritis, was
continuing to take 300 mg quinine daily as the only effec-
tive treatment for night cramps (Mackie et al. 1997).
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Figure 1. Ophthalmic condition caused by ADR, by suspected drug
(N = 36). , optic neuropathy; , maculopathy; , retinopathy; ,
angle-closure glaucoma; , other/missing.
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Amiodarone
Four patients, prescribed amiodarone for atrial fibrillation
were reported to have optic neuropathy. The two con-
firmed cases (aged 84 and 85 years) were taking several
prescribed medications but had stopped taking amioda-
rone (one after 9 months of a 200 mg daily dose; missing
data for second patient). One patient had preexisting cat-
aract in one eye but during the study period required
bilateral cataract surgery. All four cases presented with
features characteristic of bilateral amiodarone-induced
optic neuropathy (Macaluso et al. 1999; Murphy and
Murphy 2005) rather than the acute, unilateral visual loss
associated with nonarteritic ischemic optic neuropathy.
Other medications (permanent cases)
A patient requiring tissue plasminogen activator (TPA)
for postoperative uveitis following a phacotrabeculectomy
and implant of acrylic intraocular lens (IOL), experienced
opacification of the artificial lens which the reporting cli-
nician assessed as possibly due to the use of TPA in the
presence of an acrylic IOL. After removal of the IOL,
visual acuities in both eyes deteriorated leaving the
patient with permanent bilateral visual loss, possibly due
to maculopathy secondary to inflammation.
A patient with a psychiatric disorder treated with cloza-
pine had developed Bull’s eye maculopathy. Six months
after dechallenge, visual acuity had improved to 6/18 in
the better eye and visual fields had fully recovered.
A patient with optic neuropathy and probable cortical
visual loss had been treated with ten 30 mg/m2 doses of
fludarabine, in combination with cytarabine, for acute
lymphoid leukemia (MDS Trisomy 7). At follow-up,
visual acuity had improved to 6/24 in the better eye. At
notification the visual fields were reduced and color
vision and electrophysiological tests were all abnormal.
Interpretation of MRI brain findings indicated fludarabine
to be the causative drug.
A bone marrow transplant recipient with severe ante-
rior uveitis, ocular hypotony, and choroidal ciliary body
detachments had been given cidofovir for 17 days for a
disseminated Herpes Simplex infection. Normal acuities
prior to treatment were reduced to finger counting at
1 m at the first assessment and visual fields were
restricted. The patient remained visually impaired until
their death months later.
A young adult was reported with optic neuritis 3 weeks
after influenza vaccination. At follow-up, the visual acuity
in the affected eye had improved to 6/24, however, there
was a central scotoma and no color vision. At notification
the reporting clinician assessed causality by influenza
vaccination as possible but after 6 months, uncertain.
Other medications (temporary cases)
None of these patients had known eye disease or visual
loss prior to the ADR and although initially eligible, at
follow-up they were ineligible because of improved visual
function.
One patient, with unilateral sickle cell retinopathy and
abnormal ERGs, had received desferrioxamine (DFO) for
7 days to treat transfusion-related haemochromatosis. The
clinician reported reduced acuity, post-treatment, as
probable/likely due to DFO.
A patient with Crohn’s disease was reported to have
unilateral retrobulbar optic neuritis after a series of infu-
sions of Infliximab. After cessation of Infliximab, and ste-
roid therapy, visual function improved from no perceived
light to 6/5 in the affected eye.
A patient with bilateral optic neuropathy had been pre-
scribed 1 g (94 daily) of Chloramphenicol for 3 months,
to treat septic arthroplasty. At initial assessment visual
acuities were 3/24 in both eyes, visual fields reduced, and
color vision abnormal. Three weeks after dechallenge,
visual acuities were 6/9 in both eyes and visual fields and
color vision had recovered.
Four patients were reported to have angle-closure glau-
coma triggered by drugs known to have a mydriatic
effect. One patient had been prescribed a 20 mg dosage
of Citalopram for depression and anxiety 2 weeks prior
to the ADR. Although visual acuities were normal the cli-
nician was certain an adverse reaction to Citalopram had
caused unilateral glaucoma which required laser iridecto-
my surgery. Another patient, with angle-closure glau-
coma, after using an Ipratropium bromide nebulizer, was
only able to perceive light in both eyes at first assessment.
A phaco/clear lens extraction was carried out so asthma
treatment could be restarted and visual acuities recovered.
Two patients with acute visual loss due to choroidal effu-
sions and glaucoma, associated with topiramate use for
treatment of migraines, recovered visual function on
medical treatment.
Discussion
This was a time-limited national active surveillance study
of visual impairment or blindness (unilateral and bilateral
cases) due to ADR. As reported elsewhere, these events
are rare with an estimated annual incidence of fewer than
4 in 10 million adults and 1 in 100 milion children
(Cumberland et al. 2014). Most reported suspect drugs
were known to have potential adverse side-effects but this
study will increase awareness of some other drugs with
potential adverse ocular effects.
Active surveillance through BOSU has been used effec-
tively for numerous studies of rare disorders or events
ª 2014 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
2014 | Vol. 3 | Iss. 1 | e00107
Page 7
P. M. Cumberland et al. Visual Impairment Due to Adverse Drug Reactions
(Shah et al. 2011; Hamblion et al. 2012). Ascertainment
of cases via BOSU is high as assessed by indirect methods
but cannot be calculated formally in the absence of a sec-
ond independent source permitting capture/recapture
analysis (Stanford 2002). In a clinical setting, both adults
and children experiencing visual loss due to a suspected
ADR would be expected to present to an ophthalmologist,
so we expected to capture a majority of eligible cases.
Nevertheless, we recognize that underascertainment or
biased ascertainment may have occurred. As reporting by
ophthalmologists occurred after visual loss had occurred,
details for example, visual acuity before the ADR, are not
available for some cases.
Reactions to drugs with known adverse side-effects may
have been underreported and/or underreporting may have
occurred due to lack of recognition of an event as an
ADR either because the specific reaction had not been
seen before or because it was unclear the reaction was
related to the drug rather than the underlying medical
condition. Additionally, 13 of the 17 cases reported with
permanent visual loss were taking at least two other pre-
scribed drugs concurrently and identification of the drugs
causing the visual impairment was not confirmed. How-
ever, most reporting clinicians named a specific suspected
drug and graded causality as at least ‘probable/likely’. This
level of uncertainty reflects the ‘real-life’ situation of clini-
cal practice.
Suspected drugs and conditions reported
at the time of notification
Most cases (57%) were reported to have optic nerve dis-
ease due to antitubercular, antianginal, or antimicrobial
agents (Santaella and Fraunfelder 2007), with suspected
ADR due to EMB the most common cause of optic neu-
ropathy reported (12 cases in 2 years).
Arguably, more events in those taking prescribed drugs
known to induce acute angle-closure glaucoma could
have been expected over 2 years as this is not an uncom-
mon reaction with both topical and systemic medications,
particularly in elderly patients (Etminan et al. 2012; Lai
and Gangwani 2012). However, it is possible that such
acute incidents which resolved quickly and/or ADRs to
drugs with known side-effects were underreported to this
study by clinicians as the study focus was known to be
permanent visual impairment.
Hydroxychloroquine and chloroquine have been associ-
ated with many toxic effects however, serious toxicity is
very rare with recommended low dose levels (Marmor
et al. 2002; Tehrani et al. 2008). It is, therefore, notable
that the 2 cases, with normal acuities before the ADR
event, were reported to have been taking recommended
dose levels for only 1 and 2 months. respectively. These
cases highlight the critical importance of existing guide-
lines (Royal College of Ophthalmologists), ensuring that
the patient is aware of the need to stop treatment and
report any change in visual acuity or blurred vision to the
prescribing doctor.
Clinicians are regularly faced with requests to screen
patients, particularly children, who are on drugs known
to cause ADRs. Screening is a burden on patients, their
families, and the resources of Ophthalmology depart-
ments and is often not appropriate for ADRs where natu-
ral history is unknown. The onset of an ADR is not
necessarily linear with dosage and/or duration of drug
administration or necessarily correlated with reduction in
visual function, so screening those on drugs known to
have side-effects does not necessarily reduced the inci-
dence or severity of ADRs. Irrespective of whether screen-
ing can be done, the key to early recognition of toxicity is
informing the patient (or family) and where relevant, the
primary care physician, of the potential risks so as to aid
early detection and potential withdrawal of the drug to
minimize permanent visual loss.
In the UK, there is currently no way to routinely
investigate adverse ocular outcomes at a population level
to assess the proportion which might be attributable to
specific medications. The potential to use primary care
databases, such as the Clinical Practice Research Data-
link, exists but there are significant challenges to their
use in terms of accuracy and completeness of diagnosis
of ADR and coding of these events (Ackers et al. 2007).
As we have reported elsewhere (Cumberland et al. 2014)
the MHRA national system for pharmacovigilance, based
on voluntary passive surveillance, did not prove to be as
efficient as active surveillance through BOSU. However,
the MHRA have recently published new guidance on
reporting suspected ADRs in children http://www.mhra.
gov.uk/Safetyinformation/DrugSafetyUpdate/CON444290,
which specifies that all reactions associated with use of
off-label and unlicensed (OLUL) medicines, which are
more likely to be implicated in an ADR than authorized
medicines (Bellis et al. 2014), should be reported via the
Yellow Card Scheme. The MHRA guidance notes also
highlight the importance of vigilance in monitoring
elderly patients who, for both pharmacokinetic and phar-
modynamic reasons, may be more susceptible to devel-
oping ADRs. If MHRA guidance is followed and the
information collected is fed back to clinical practice, this
has the potential to improve routine surveillance in the
future.
This study has highlighted the ongoing challenges in
monitoring ADRs which underlie the presently incom-
plete evidence database for recommendations about
screening. There were a few ineligible cases, with mild or
moderate visual loss, notified to the study which high-
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lights a need to also understand the considerable burden
of mild or moderate visual impairment due to ADR,
which was not evaluated by this study. Faced with the
challenges of voluntary reporting to the national monitor-
ing scheme that we have reported elsewhere, this method
of active surveillance has been able to provide otherwise
inaccessible information on ADRs and demonstrate clini-
cal scenarios at a level of detail which is informative to
practitioners. It was also useful in creating awareness of
the previously unknown potential of some medications to
cause ADRs.
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